Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Allison

Showing results (591-600 of 647) with videos related to

Pageof 65
Sort By:
Science Translational Medicine|April 20, 2022
A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapyPavlos Msaouel, Sangeeta Goswami, Peter F Thall, et al.
Nature Communications|August 31, 2016
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activityChia-Wei Li, Seung-Oe Lim, Weiya Xia, et al.
Nature Communications|September 8, 2017
HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genesRina M Mbofung, Jodi A McKenzie, Shruti Malu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2023
Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch SyndromeNan Deng, Laura Reyes-Uribe, Johannes F Fahrmann, et al.
Cancer|December 1, 2018
The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemiaPatrick Williams, Sreyashi Basu, Guillermo Garcia-Manero, et al.
Cell Research|March 4, 2015
Erratum: anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25Dalil Hannani, Marie Vétizou, David Enot, et al.
Cancer Discovery|November 10, 2018
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II StudyNaval Daver, Guillermo Garcia-Manero, Sreyashi Basu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 28, 2016
A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune ProfilingHeather L McArthur, Adi Diab, David B Page, et al.
Nature|November 17, 2022
T cells specific for α-myosin drive immunotherapy-related myocarditisMargaret L Axelrod, Wouter C Meijers, Elles M Screever, et al.
Nature Medicine|November 14, 2018
Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitisYinghong Wang, Diana H Wiesnoski, Beth A Helmink, et al.
Pageof 65

Showing results (591-600 of 647) with videos related to

Sort By:
Pageof 65
Science Translational Medicine|April 20, 2022
A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapyPavlos Msaouel, Sangeeta Goswami, Peter F Thall, et al.
Nature Communications|August 31, 2016
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activityChia-Wei Li, Seung-Oe Lim, Weiya Xia, et al.
Nature Communications|September 8, 2017
HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genesRina M Mbofung, Jodi A McKenzie, Shruti Malu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2023
Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch SyndromeNan Deng, Laura Reyes-Uribe, Johannes F Fahrmann, et al.
Cancer|December 1, 2018
The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemiaPatrick Williams, Sreyashi Basu, Guillermo Garcia-Manero, et al.
Cell Research|March 4, 2015
Erratum: anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25Dalil Hannani, Marie Vétizou, David Enot, et al.
Cancer Discovery|November 10, 2018
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II StudyNaval Daver, Guillermo Garcia-Manero, Sreyashi Basu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 28, 2016
A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune ProfilingHeather L McArthur, Adi Diab, David B Page, et al.
Nature|November 17, 2022
T cells specific for α-myosin drive immunotherapy-related myocarditisMargaret L Axelrod, Wouter C Meijers, Elles M Screever, et al.
Nature Medicine|November 14, 2018
Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitisYinghong Wang, Diana H Wiesnoski, Beth A Helmink, et al.
Pageof 65